ARTICLE | Clinical News
Secnidazole: Completed Phase III enrollment
September 7, 2015 7:00 AM UTC
Symbiomix completed enrollment of 189 patients in a double-blind, placebo-controlled, U.S. Phase III trial evaluating a single dose of 2 g oral SYM-1219. FDA also granted Fast Track designation to SYM...